Steady-state pharmacokinetics of abacavir in plasma and intracellular carbovir triphosphate following administration of abacavir at 600 milligrams once daily and 300 milligrams twice daily in human immunodeficiency virus-infected subjects.
about
Abacavir/lamivudine combination in the treatment of HIV: a review.Lack of association between stavudine exposure and lipoatrophy, dysglycaemia, hyperlactataemia and hypertriglyceridaemia: a prospective cross sectional studyAbacavir/lamivudine fixed-dose combination antiretroviral therapy for the treatment of HIV.Abacavir increases platelet reactivity via competitive inhibition of soluble guanylyl cyclaseCombination nucleoside/nucleotide reverse transcriptase inhibitors for treatment of HIV infection.Pharmacokinetics of abacavir and its anabolite carbovir triphosphate without and with darunavir/ritonavir or raltegravir in HIV-infected subjects.Plasma pharmacokinetics of once-daily abacavir- and lamivudine-containing regimens and week 96 efficacy in HIV-infected Thai childrenQuantification of cell-associated atazanavir, darunavir, lopinavir, ritonavir, and efavirenz concentrations in human mononuclear cell extracts.Mass spectrometry in the quantitative analysis of therapeutic intracellular nucleotide analogs.Clinical pharmacology profile of raltegravir, an HIV-1 integrase strand transfer inhibitor.Abacavir and lamivudine for the treatment of human immunodeficiency virus.Clinical pharmacokinetics and pharmacodynamics of dolutegravir used as a single tablet regimen for the treatment of HIV-1 infection.Liquid chromatography-mass spectrometry methods for the intracellular determination of drugs and their metabolites: a focus on antiviral drugs.Out of focus: tailoring the cascade of care to the needs of women living with HIV.Dolutegravir and elvitegravir plasma concentrations following cessation of drug intake.Pharmacokinetic study of once-daily versus twice-daily abacavir and lamivudine in HIV type-1-infected children aged 3-<36 months.Stress Degradation Behavior of Abacavir Sulfate and Development of a Suitable Stability-Indicating UHPLC Method for the Determination of Abacavir, its Related Substances, and Degradation Products.Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots following Directly Observed Therapy: the DOT-DBS Study.Simultaneous quantification of intracellular lamivudine and abacavir triphosphate metabolites by LC-MS/MS.
P2860
Q33715435-854F730B-8334-4E35-9FDE-203357F43450Q34039225-E38DC564-CE20-4FC8-A639-D282BD7775C3Q35233168-81859795-0337-49A2-A59F-E2CADE42C326Q35737682-99B5B34F-D225-402A-AD9C-6FE1A4D81904Q36097686-6896743D-1C4D-4301-AC42-ACBEAFC5D01AQ37077340-03B1B120-EC48-4FEE-A5B4-F1AD8BF86B42Q37098376-E42B5F21-B416-4941-883D-F37ED6BF38B6Q37713065-46627A41-6C32-4617-B7AD-01633EA23D24Q37771921-36A7D104-BE7C-4791-A0A9-2CD47786CE0FQ37826300-D4D10D7A-CD5B-40E7-BB59-DF50A8846B49Q37905058-6F742894-8570-4161-8B72-A2AA5574EFB8Q38541809-90CD390D-6672-4743-A132-98E8B9501692Q39434360-EAA6C389-111A-4E30-B8DA-BEE44EC15ABDQ40062892-2A511170-58CE-4FBF-B4E2-469EDE0F95BBQ40199953-2783162B-2F53-4CC4-B917-802FB91DC749Q41881433-0E46AAEB-A711-4A4E-87D5-92999F0F589CQ42425202-A46201CF-B385-4994-9A32-8ED922021C6EQ46323872-DB23A082-8179-41B2-9D47-18A12FCD5C0AQ52666512-D3C81EC9-059A-4471-B0F8-7C9C6D2C9566
P2860
Steady-state pharmacokinetics of abacavir in plasma and intracellular carbovir triphosphate following administration of abacavir at 600 milligrams once daily and 300 milligrams twice daily in human immunodeficiency virus-infected subjects.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 02 February 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Steady-state pharmacokinetics ...... iency virus-infected subjects.
@en
Steady-state pharmacokinetics ...... iency virus-infected subjects.
@nl
type
label
Steady-state pharmacokinetics ...... iency virus-infected subjects.
@en
Steady-state pharmacokinetics ...... iency virus-infected subjects.
@nl
prefLabel
Steady-state pharmacokinetics ...... iency virus-infected subjects.
@en
Steady-state pharmacokinetics ...... iency virus-infected subjects.
@nl
P2093
P2860
P356
P1476
Steady-state pharmacokinetics ...... iency virus-infected subjects.
@en
P2093
Carl Fletcher
Chris Higgs
Elena M Guerini
Geoffrey J Yuen
Graeme Moyle
Ivy H Song
Marta Boffito
Phillip E Hay
Sherene S Min
P2860
P304
P356
10.1128/AAC.01000-08
P407
P577
2009-02-02T00:00:00Z